Thrombolex, Inc.

Thrombolex, Inc.

Private
New Britain, PennsylvaniaHealthcare & Life Scienceshttps://thrombolex.com

Last Round

Series A

Mar 12, 2026

Total Funding Raised

$13.82M

Company Overview

Thrombolex, Inc. is a medical device company that designs, develops, and distributes innovative endovascular catheters used in interventional procedures for patients who suffer from arterial and venous thromboembolic conditions.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices

Business Model

B2B

Customer Profile

Hardware Sales, Government Contracts

AI Layer

Non-AI

Keywords

endovascular catheterpulmonary embolismPEdeep vein thrombosisDVTcatheter-directed thrombolysisthrombectomy devicepharmaco-mechanical thrombectomyvenous thromboembolismVTEclot removal deviceinterventional radiologyinterventional cardiologyclot fragmentationmedical deviceFDA 510(k) clearancevascular surgery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Thrombolex, Inc. Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Thrombolex, Inc. Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series AMar 12, 2026
Series BJun 4, 2024
VC RoundAug 30, 2022
VC RoundNov 29, 2021
GrantJul 7, 2020
Series A
Feb 3, 2020

Thrombolex, Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 21, 2026

    Monthly visitors increased 154% MoM, reaching 3K.

  • Mar 16, 2026

    Clay DeMarcus of OrbiMed joins the Board of Directors.

Thrombolex, Inc. Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Thrombolex, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Thrombolex, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersNew Britain, Pennsylvania
Employee Range18
Year Founded2016
Last FundingMar 12, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.